NeueHealth Q2 2024 Earnings Call Transcript

Quartr
Provided by Quartr
August 7, 2024

There are 4 speakers on the call.

Operator

Good morning all and welcome to the NueHealth Q2 twenty twenty four Earnings Call. My name is Carly, and I'll be your call coordinator today. I would like to hand over to your host, Emily Lombardi.

Operator

Please begin.

Speaker 1

Good morning, and welcome to NueHealth's 2nd quarter 2024 earnings conference call. As a reminder, this call is being recorded. Leading the call today are NueHealth's President and CEO, Mike Miken and CFO, Jay Matusiak. Before we begin, we want to remind you that this call may contain forward looking statements under U. S.

Speaker 1

Federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. A description of some of the risks and uncertainties can be found in the reports that we file with the Securities and Exchange Commission, including the risk factors in our current and periodic reports we file with the SEC. Except as required by law, we undertake no obligation to revise or update any forward looking statements or information. This call will also reference non GAAP amounts and measures.

Speaker 1

A reconciliation of the non GAAP to GAAP measures is available in the company's 2nd quarter earnings release, available on the company's Investor Relations page at investors. Newhealth.com. Information presented on this call is contained in such earnings release that we issued this morning in our Form 8 ks dated August 7, 2024, and in the related presentation, each of which may be accessed from the Investor Relations page of the company's website. With that, I will now turn the conference over to NueHealth's Chief Executive Officer, Mike Mikan.

Speaker 2

Good morning, everyone, and thank you for joining NueHealth's Q2 2024 Earnings Call. NueHealth delivered solid results in the Q2 as we continue to drive value for consumers, providers and payers across the healthcare industry. On June 24, we announced that we secured up to $150,000,000 in a new term loan facility with Hercules Capital. This significantly strengthens our capital position and underscores our ability to deliver high quality affordable healthcare to all populations. We are excited to have Hercules support and believe we are well positioned to continue to drive long term sustainable growth in 2024 and beyond.

Speaker 2

Throughout the second quarter, we continued to advance our value driven consumer centric care model, which we believe uniquely aligns interests clinically, financially and through data and technology to create a seamless, more coordinated healthcare experience. We are confident in our model and its ability to drive better health outcomes for all populations. I'll start by mentioning a few reasons why we believe our model is well positioned for the future. 1st, we believe our value driven care model is carefully designed to improve upon traditional approaches to care delivery, which have revolved around episodic encounters and led to costly fragmented care. In contrast, our model is grounded in the power of long standing relationships.

Speaker 2

We believe we are building trusted ongoing relationships with our consumers in the local communities we serve and fostering strong partnerships with payers and providers across the country. By doing so, we believe we have established trust and confidence with stakeholders throughout the healthcare industry and we expect to continue to build upon these relationships in the years to come. 2nd, our model is built to serve all populations and partner with a diverse set of providers. In the Q2, we served over 477,000 consumers across the ACA Marketplace, Medicare and Medicaid. We continue to believe this model demonstrates our ability to effectively manage populations across product categories, delivering personalized care no matter the need or circumstance.

Speaker 2

In addition to serving a diverse consumer base, we partner with a diverse set of providers. Across our new care and new solutions business segments, we continue to partner with providers through our own clinics in Florida and Texas as well as affiliated providers across the country as we enable them to succeed in performance based arrangements. We have deep experience working with a broad variety of provider groups, no matter where they are on their path to taking risk. Overall, we see our diverse and balanced portfolio as key to expanding our value based footprint in the future, while mitigating risk associated with high concentration in any one area. Finally, we believe our model is well positioned for the future as it places the consumer at the center of everything we do.

Speaker 2

We are focused on taking a proactive approach to consumer engagement, which is reflected in our commitment to understanding each consumer holistically, developing personalized care plans and maintaining an ongoing relationship throughout the consumer's entire healthcare journey. We are partners in care and this is reflected in every interaction we have with our consumers. As our model continues to drive strong results, we are carefully evaluating strategic growth opportunities, many of which continue to surface organically from existing partnerships and the relationships we have formed across the industry. We have a robust pipeline in place for 2025 beyond as we continue to review capital efficient opportunities to expand our payer and provider partnerships and grow the consumers we serve in both current and new geographies. In the Q2, NueHealth delivered enterprise adjusted EBITDA of $4,000,000 Overall, we believe our differentiated care model positions us to continue to drive strong results for the remainder of 2024 and beyond.

Speaker 2

I'll now provide a brief update on our New Care and New Solutions business segments. In our New Care segment, positive momentum continued in the 2nd quarter as we delivered segment adjusted EBITDA of $13,500,000 We are prioritizing engaging all consumers and delivering consumer centric care that's tailored to meet specific needs, preferences and circumstances. In our clinics, we demonstrated resilience and strength in the wake of several severe storms impacting Texas and Florida over the past several months. Aligned with our consumer centric approach to care, our teams came together to ensure consumers, our patients, continue to receive the care they needed, helping to coordinate appointments and telehealth visits and keeping the patient at the center of all we do. I am proud of our teams and their dedication to delivering high quality care no matter the circumstance.

Speaker 2

New solutions continues to focus on partnering with providers and enabling them to thrive in performance based arrangements through our suite of population health tools and capabilities as well as driving results through our participation in ACO Reach. Our provider enablement business served approximately 113,000 consumers in the 2nd quarter. This exceeded our expectations and we believe it shows the value we are bringing to providers and their confidence in our ability to help them navigate the industry's shift to value based care. We believe the strong relationships we are building with providers in this part of our business continue to offer an avenue for future growth opportunities across our new care and new solutions business segments. In our ACO Reach business, we drove strong performance, consistent with our expectations in the 2nd quarter as we maintain our focus on key care management, patient engagement and health equity initiatives to deliver high quality care to our Medicare beneficiaries.

Speaker 2

I'll now hand it over to Jay to provide additional details on the Q2 financial results.

Speaker 3

Thank you, Mike, and good morning, everyone. I'll start by reviewing our Q2 financial performance for our consolidated new health business as well as each of our new care and new solutions segments. Then I'll briefly touch on the wind down of our ACA Insurance business and go over our balance sheet. Finally, I'll review our 2024 outlook. As a reminder, I will be focusing on the 2024 financial results of our continuing new health business in each of our new care and new solutions segments.

Speaker 3

GAAP financials are included in our earnings release and contain results that include our discontinued operations. NueHealth consolidated revenue for the Q2 was $226,000,000 with gross margin of 48,300,000 dollars NueHealth delivered adjusted EBITDA of $4,000,000 in the 2nd quarter, serving approximately 477,000 consumers across our new care and new solutions business segments. This is a moderate increase in consumers served over the Q1 and we continue to expect to generate increased growth in the second half of the year. We are reaffirming our expectation for full year adjusted EBITDA of between $15,000,000 $25,000,000 Turning now to our Nu Care segment. In the 2nd quarter, Nu Care revenue was $77,000,000 in line with our expectations.

Speaker 3

Starting in the Q3, we have contracts in place with payer partners that are expected to increase our clinic volume and drive further growth in the 3rd and 4th quarters. In the Q2, new care operating costs were higher than expected due to a long lived asset impairment expense tied to classifying our associates MD clinics as held for sale. This is immaterial to our business overall and we will continue to partner with our associates MD clinics through our affiliate business moving forward. Excluding this adjustment, Nucare operating costs were in line with expectations and Nucare operating income was $8,500,000 for the 2nd quarter. Including the long lived asset impairment expense, Nucare operating loss was $5,900,000 for the quarter.

Speaker 3

In our new solutions segment, revenue was $152,100,000 in the second quarter. 2nd quarter operating costs were in line with expectations with medical costs moderately lower. New Solutions segment operating loss was $397,000 for the 2nd quarter. Our ACO Reach business continues to deliver strong performance in line with our expectations and we are pleased with the progress we are making in this part of our business in the first half of the year with a strong portfolio of aligned provider partners. On the provider enablement side of new solutions, we are generating strong results our capabilities and expertise in performance based arrangements, driving value for the provider partners across the country.

Speaker 3

In the second quarter, we served approximately 113,000 consumers through this business, exceeding our expectations. We look forward to continuing to build relationships with providers no matter where they are on their path to participating in performance based arrangements. Next, I'll briefly address the wind down of our AC insurance business. We are continuing to make progress as planned in the Q2. At the end of the Q2, our ACA Insurance business had approximately $135,000,000 in excess cash after reserving for expected medical costs and other anticipated wind down expenses, not including risk adjustment obligations due under our repayment agreements with CMS.

Speaker 3

We continue to retrieve capital from our discontinued entities and have received approximately $28,200,000 so far this year, some of which has been infused into states with repayment agreements. We have made several prepayments to CMS already this year. Overall, we believe our business is in a much stronger and more predictable position this year as we continue to see the remaining liability associated with our ACA insurance business steadily decline. Now turning to our balance sheet. As of June 30, 2024, we had $277,800,000 in total cash and investments, including amounts in our regulated entities.

Speaker 3

Our non regulated cash and short term investments were $142,200,000 at the end of the second quarter, including $60,700,000 of restricted cash and investments. As Mike mentioned earlier, on June 24, we were pleased to announce that we had entered into a secured loan facility for up to $150,000,000 with Hercules Capital. This is significant as it meaningfully strengthens our balance sheet and provides a solid foundation for our company to execute against our strategic priorities in 2024 and beyond. Turning now to our 2024 outlook. In 2024, we are confirming our expectations for enterprise adjusted EBITDA to be between $15,000,000 $25,000,000 We are now expecting consolidated revenue of approximately $950,000,000 Specifically, we expect approximately $320,000,000 from our New Care segment and approximately $640,000,000 from our New Solutions segment.

Speaker 3

We are confirming our expectations to serve between 475,500,000 consumers across both our New Care and New Solutions segments and we anticipate reaching the high end of this range by the end of 2024. We expect to serve between 330,000,345,000 value based consumers in our clinics and between 145,000 and 155,000 consumers in new solutions, including approximately 45,000 through ACL Reach. Finally, we expect our adjusted operating cost ratio to be between 15% 16% excluding corporate costs. When you include corporate costs, this is 19% to 20%. Overall, our 2nd quarter results reflect strong performance in both our new care and new solutions business segments, and we look forward to continuing to build on this momentum in the second half of the year.

Speaker 3

I'll now turn it back over to Mike for some closing remarks.

Speaker 2

Thank you, Jay. As we've outlined this morning, we delivered strong performance in the Q2 as we advanced our value driven consumer centric care model and continue to make high quality healthcare more accessible and affordable for all populations. We believe we are well positioned for 2025 and beyond with a differentiated model that prioritizes strong ongoing relationships and proactive consumer engagement. Our commitment to aligning the interests of consumers, providers and payers to create a better health care experience has never been stronger and we are eager to continue to advance our model in collaboration with our partners. I would like to thank the entire NueHealth team for their continued dedication to transforming healthcare.

Speaker 2

I look forward to building on our momentum in the second half of 2024 and beyond. That concludes today's call. Thank you for joining and for your interest in NewHealth.

Operator

This concludes today's call. Thank you to everyone for joining. You may now disconnect your lines.

Powered by Quartr

Key Takeaways

  • On June 24, NueHealth secured up to $150 million in a new term loan facility with Hercules Capital, significantly strengthening its capital position for sustainable growth.
  • In Q2, consolidated revenue reached $226 million with adjusted EBITDA of $4 million, serving approximately 477,000 consumers across its New Care and New Solutions segments.
  • The New Care segment delivered segment adjusted EBITDA of $13.5 million, and expects clinic volume growth from new payer contracts starting in Q3.
  • New Solutions reported $152.1 million in revenue with a $0.4 million operating loss while serving 113,000 consumers and achieving strong performance in its ACO Reach program.
  • For full-year 2024, NueHealth reaffirmed guidance of $950 million in revenue, $15–25 million in adjusted EBITDA, service for over 475,000 consumers and an adjusted operating cost ratio of 19–20% including corporate costs.
AI Generated. May Contain Errors.
Earnings Conference Call
NeueHealth Q2 2024
00:00 / 00:00